GlassScriptPhysician profile
Anthony G Cerullo
NPI 1346271210
$7,200.00
in general payments reported to CMS, 2019-2025
46 companies · $1,389 in 2025
The $1,389 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,458 · 2022: $1,221 · 2023: $1,739 · 2024: $1,392 · 2025: $1,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,421 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,420.71 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,179.01 | 2021-2025 | |
| Novo Nordisk INC | $1,020.72 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $925.46 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $559.18 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $463.51 | 2021-2025 | |
| Astellas Pharma US INC | $353.47 | 2022-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $279.48 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Esperion Therapeutics, INC. | $233.51 | 2021-2025 | Nexletol |
| Amgen INC. | $202.86 | 2021-2025 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $185.69 | 2021-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Biohaven Pharmaceutical Holding Company LTD. | $183.17 | 2022 | |
| Bausch Health US, LLC | $138.34 | 2021-2023 | Aplenzin |
| Biohaven Pharmaceuticals, INC. | $125.84 | 2021 | |
| Edwards Lifesciences Corporation | $111.03 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Sanofi Pasteur INC. | $106.87 | 2021-2024 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $91.43 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.34 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $88.72 | 2022-2024 | Quviviq |
| Aimmune Therapeutics, INC. | $86.38 | 2024-2025 | Zenpep |
| Exact Sciences Corporation | $67.21 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Seqirus USA INC | $55.54 | 2024-2025 | Flucelvax, Fluad |
| Exeltis, USA INC. | $51.82 | 2023-2024 | Slynd |
| Cranial Technologies, INC | $51.76 | 2022-2025 | Doc Band |
| Bayer Healthcare Pharmaceuticals INC. | $49.61 | 2022-2023 | |
| Nevro Corp. | $38.34 | 2022-2023 | Senza |
| Genentech USA, INC. | $36.27 | 2021-2022 | |
| Philips North America LLC | $35.10 | 2024 | (Ck7) Extended Holter |
| Amarin Pharma, INC. | $33.44 | 2021 | |
| Amneal Pharmaceuticals LLC | $30.26 | 2023 | Unithroid |
| Sanofi-Aventis U.S. LLC | $30.20 | 2021 | |
| Ibsa Pharma INC. | $24.08 | 2025 | Tirosint, Flector, Licart |
| Hologic Sales and Service, LLC | $23.70 | 2025 | Thinprep 2000 Processor, Aptima |
| Inspire Medical Systems, INC. | $22.39 | 2023 | Inspire |
| Phadia US INC. | $21.70 | 2025 | Immunocap |
| Axsome Therapeutics, INC. | $19.74 | 2025 | Auvelity |
| Boston Scientific Corporation | $19.50 | 2023 | |
| Vertical Pharmaceuticals, LLC | $18.96 | 2025 | Relexxii |
| Organon LLC | $18.95 | 2025 | Nexplanon |
| Impel Pharmaceuticals INC. | $18.65 | 2022 | |
| Gilead Sciences, INC. | $17.83 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $17.62 | 2022 | |
| Inogen, INC. | $15.62 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Janssen Pharmaceuticals, INC | $14.58 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.58 | 2022 | |
| Medtronic, INC. | $13.87 | 2025 | Inceptiv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Cerullo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.